Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)
Autor: | Peters, S. Dafni, U. Boyer, M. De Ruysscher, D. Faivre-Finn, C. Felip, E. Garrido, P. Girard, N. Guckenberger, M. Haanen, J. Le Pechoux, C. Mornex, F. Ozsahin, M. Paz-Ares, L. Planchard, D. Raben, D. Ramalingam, S. Reck, M. Smit, E. Stahel, R. Stenzinger, A. Swanton, C. Vallone, S. Garassino, M.C. |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Databáze: | OpenAIRE |
Externí odkaz: |